Floatz logo

rxc007

IPF

Redx Pharma LtdPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

110 Active assets in the IPF cohort.

Asset / SponsorPhaseRating
Pirfenidone
Endeavor Biomedicines, Inc.
Phase 4A
N-Acetyl-L-Cysteine
Endeavor Biomedicines, Inc.
Phase 4BBB
Nintedanib
Mannkind Corporation
Phase 4BBB
PREDNISONE TABLETS
Fondation Hôpital Saint-Joseph
Phase 3BB
hsk44459
Haisco Pharmaceutical Group Co., Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

rxc007 is also rated in:

kidney disorderDormant
CC
Indicative ·
47 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
CC
Indicative ·
46 / 100
View asset →
liver disorderDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →